IMI2 1st call for proposals 2014
With regards to Type 1 diabetes, the aims to bring
together leading clinicians and researchers from the areas of
immunology, beta cell biology, and biomarker research from academia and
industry. Participants should focus on providing an improved molecular
understanding of the T1DM patients, delivering insights into the disease
heterogeneity and providing tools for the identification of high-risk
patients - with a view to create a foundation for personalised therapy
of T1DM patients.
For retinal diseases, on the other hand, the aim is to evaluate
novel endpoint candidates for dry AMD (Age-Related Macular Degeneration)
and DR (Diabetic retinopathy). The evaluation should cover the
technical, medical and health economic appropriateness of a method and
bridge preclinical and clinical studies.
The data generated is expected to serve as a basis for initial
discussion with regulatory agencies and/or HTA-bodies towards the
acceptance of the resulting outcomes as endpoints for future clinical
programmes.
Official call announcements - participant portal